Ocumension Therapeutics (HK:1477)
:1477
Want to see HK:1477 full AI Analyst Report?
1477 Stock Chart & Stats
HK$7.55
-HK$0.01(-0.25%)
At close: 4:00 PM EST
HK$7.55
-HK$0.01(-0.25%)
Day’s Range― - ―
52-Week RangeHK$6.00 - HK$12.23
Previous CloseN/A
Volume1.11M
Average Volume (3M)3.41M
Market Cap
HK$5.09B
Enterprise ValueHK$4.13B
Total Cash (Recent Filing)HK$402.63M
Total Debt (Recent Filing)HK$187.62M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.43
Price to Sales (P/S)6.54
P/FCF Ratio-14.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.16Price Target Upside34.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$1.10B
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration & Solid Gross MarginSustained +44% revenue growth with ~44% gross margin indicates durable commercial traction in ophthalmology. This combination supports scalable unit economics, funds continued R&D/commercial investment, and improves the odds of reaching sustained operating profitability if growth persists.
Conservative Balance Sheet And Low LeverageVery low leverage provides financial flexibility to fund clinical programs and commercialization without immediate refinancing pressure. A strong equity base and modest debt lower insolvency risk and give management optionality to time capital raises or M&A from a position of strength.
Improving Loss TrajectoryNarrowing losses alongside accelerating sales suggest the business model is moving toward break-even. A persistent improvement trend reduces long-term dilution risk, increases investor confidence in execution, and can materially lower future external funding needs if sustained.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the company cannot self-finance growth or R&D. Continued cash burn forces reliance on markets or partners, increases refinancing and timing risk, and can constrain strategic flexibility if capital access tightens.
Ongoing Net Losses And Negative MarginsA persistent -20% net margin and negative operating profits indicate the portfolio has not yet achieved sustainable profitability. This limits internal capital generation, depresses returns on equity, and raises the probability of future equity dilution to cover operating and development costs.
Reliance On External Capital For OperationsDependence on external funding creates execution risk tied to market conditions and investor appetite. Fundraising needs can lead to dilution, conditional partnerships, or curtailed programs if capital becomes expensive or scarce, constraining long-term strategic autonomy.
Ocumension Therapeutics News
1477 FAQ
What was Ocumension Therapeutics’s price range in the past 12 months?
Ocumension Therapeutics lowest stock price was HK$6.00 and its highest was HK$12.23 in the past 12 months.
What is Ocumension Therapeutics’s market cap?
Ocumension Therapeutics’s market cap is HK$5.09B.
When is Ocumension Therapeutics’s upcoming earnings report date?
Ocumension Therapeutics’s upcoming earnings report date is Aug 20, 2026 which is in 88 days.
How were Ocumension Therapeutics’s earnings last quarter?
Ocumension Therapeutics released its earnings results on Mar 26, 2026. The company reported -HK$0.046 earnings per share for the quarter, beating the consensus estimate of -HK$0.081 by HK$0.035.
Is Ocumension Therapeutics overvalued?
According to Wall Street analysts Ocumension Therapeutics’s price is currently Undervalued.
Does Ocumension Therapeutics pay dividends?
Ocumension Therapeutics does not currently pay dividends.
What is Ocumension Therapeutics’s EPS estimate?
Ocumension Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Ocumension Therapeutics have?
Ocumension Therapeutics has 836,331,900 shares outstanding.
What happened to Ocumension Therapeutics’s price movement after its last earnings report?
Ocumension Therapeutics reported an EPS of -HK$0.046 in its last earnings report, beating expectations of -HK$0.081. Following the earnings report the stock price went down -0.996%.
Which hedge fund is a major shareholder of Ocumension Therapeutics?
Currently, no hedge funds are holding shares in HK:1477
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocumension Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.56%
12-Months-Change
Fundamentals
Return on Equity
-4.33%
Trailing 12-Months
Asset Growth
7.75%
Trailing 12-Months
Company Description
Ocumension Therapeutics
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.
1477 Stock 12 Month Forecast
Average Price Target
HK$10.16
▲(34.57% Upside)
Technical Analysis
Jiangsu Recbio Technology Co., Ltd. Class H
―
Mabpharm Limited
―
Zhaoke Ophthalmology Ltd.
―
Transcenta Holding Limited
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---